Eloctate vs Hemlibra
Side-by-side cost comparison based on Medicare Part D data
Eloctate
Antihemophilic Factor (FC fusion)
Manufactured by Sanofi
Hemlibra
Emicizumab
Manufactured by Genentech/Roche
Eloctate costs 8% less per claim than Hemlibra ($31,500.00 vs $34,278.00). A generic version of Eloctate is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Eloctate | Hemlibra |
|---|---|---|
| Avg Cost Per Claim | $31,500.00 | $34,278.00 |
| Total Medicare Spending | $567.0M | $1.2B |
| Total Beneficiaries | 2,100 | 4,200 |
| Total Claims | 18,000 | 36,000 |
| Annual Cost/Patient | $270,000.00 | $293,810.00 |
| Year-over-Year Change | -4.6% | +18.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Sanofi | Genentech/Roche |
| Condition | Blood Disorders | Blood Disorders |
| Generic Name | Antihemophilic Factor (FC fusion) | Emicizumab |
Eloctate vs Hemlibra: What the Data Shows
Eloctate (Antihemophilic Factor (FC fusion)) and Hemlibra (Emicizumab) are both used to treat blood disorders. Based on Medicare Part D data, Eloctate costs $31,500.00 per claim, which is 8% less than Hemlibra at $34,278.00 per claim.
Medicare spent $567.0M on Eloctate and $1.2B on Hemlibra. In terms of patient reach, Hemlibra serves more beneficiaries (4,200 vs 2,100).
Year-over-year spending changed -4.6% for Eloctate and +18.6% for Hemlibra. Hemlibra saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Eloctate is cheaper at $31,500.00 per claim, compared to $34,278.00 for Hemlibra. That makes Eloctate about 8% less expensive per claim based on Medicare Part D data.
Yes, both Eloctate and Hemlibra are used to treat blood disorders. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Antihemophilic Factor (FC fusion) and generic Emicizumab can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Eloctate covering 2,100 beneficiaries, and $1.2B on Hemlibra covering 4,200 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.